Abetimus

Drug Profile

Abetimus

Alternative Names: Abetimus sodium; LJP 394; Riquent

Latest Information Update: 16 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Oligonucleotides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lupus nephritis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 12 Feb 2009 Discontinued - Phase-III for Lupus nephritis in Asia (IV)
  • 12 Feb 2009 Discontinued - Phase-III for Lupus nephritis in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top